Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez)

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials... Curr Breast Cancer Rep (2011) 3:1–3 DOI 10.1007/s12609-010-0032-2 CLINICAL TRIAL REPORT Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez) Antonio C. Wolff Published online: 18 December 2010 Springer Science+Business Media, LLC 2010 Rating outcome of patients with early-stage HER2-positive disease treated with adjuvant trastuzumab may now surpass that of �� Of major importance patients whose tumors lack over-expression or gene amplification. Approximately 15% of patients with HER2-positive Introduction disease still recur within 5 years despite adjuvant trastuzu- mab. Mechanisms of resistance may include heterodimer It has been close to 25 years since the first reports on the signaling of other HER proteins, activation of the p95 association between amplification of the human epidermal truncated form of HER2, and cross-talk with other receptor growth receptor 2 gene (HER2) and inferior outcomes in pathways [6]. p95HER2 expression is observed in approx- breast cancer [1]. HER2 was soon recognized as a strong imately 25% of HER2-positive tumors, and intrinsic prognostic marker for poor outcome, and assays to detect activation of the kinase domain may explain the inferior gene amplification and protein over-expression in formalin- clinical outcome [7]. New therapies are under http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez)

Current Breast Cancer Reports , Volume 3 (1) – Dec 18, 2010

Loading next page...
 
/lp/springer-journals/adjuvant-lapatinib-and-or-trastuzumab-treatment-optimisation-the-altto-uXoCWF3m23

References (17)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Surgical Oncology; Internal Medicine; Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-010-0032-2
Publisher site
See Article on Publisher Site

Abstract

Curr Breast Cancer Rep (2011) 3:1–3 DOI 10.1007/s12609-010-0032-2 CLINICAL TRIAL REPORT Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez) Antonio C. Wolff Published online: 18 December 2010 Springer Science+Business Media, LLC 2010 Rating outcome of patients with early-stage HER2-positive disease treated with adjuvant trastuzumab may now surpass that of �� Of major importance patients whose tumors lack over-expression or gene amplification. Approximately 15% of patients with HER2-positive Introduction disease still recur within 5 years despite adjuvant trastuzu- mab. Mechanisms of resistance may include heterodimer It has been close to 25 years since the first reports on the signaling of other HER proteins, activation of the p95 association between amplification of the human epidermal truncated form of HER2, and cross-talk with other receptor growth receptor 2 gene (HER2) and inferior outcomes in pathways [6]. p95HER2 expression is observed in approx- breast cancer [1]. HER2 was soon recognized as a strong imately 25% of HER2-positive tumors, and intrinsic prognostic marker for poor outcome, and assays to detect activation of the kinase domain may explain the inferior gene amplification and protein over-expression in formalin- clinical outcome [7]. New therapies are under

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Dec 18, 2010

There are no references for this article.